MedTrace Logo

A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

NCT04470830 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 718

Last updated 2023-10-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values, serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).

Conditions

  • Essential Hypertension

Sponsors & Collaborators

  • Celltrion Pharm, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-11
Primary Completion
2023-05-25
Completion
2023-05-25

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470830 on ClinicalTrials.gov